A survey of 1422 non-Hodgkin's lymphoma (NHL) patients who were diagnosed at the Korea Institute of Radiological & Medical Sciences between 1989 and 2004 identified 28 patients with PLB (2%). In 18 of these cases, fluorodeoxyglucose positron emission tomography (FDG-PET) was used for evaluation of diagnosis and response, and for recurrence cases. All 18 cases were reviewed and confirmed with bone biopsy by an experienced hematopathologist. The clinical data and imaging findings of these 18 patients were monitored during treatment and follow-up period for changes in the imaging findings. All study findings were retrospectively interpreted jointly and in consensus by one radiologist and two nuclear physicians. All computed tomography (CT) or magnetic resonance imaging (MRI) scans of the involved lesions were timed to coincide with the PET images. We analyzed the clinical relevance of the separate imaging findings. The effects in staging, response and recurrence evaluation were determined according to the final clinical decisions.
The study population is summarized in Table 1. The number of patients in whom PET findings would contribute to treatment decisions in addition to clinical findings was 15 out of 18 patients. PET contributed in the staging of 12 PBLs with polyostotic lesions. Five patients in whom there were difficulties in evaluating the response turned out to have CR during the follow-up period. The lesion finding resolved on a subsequent PET scan, with rapid decline of FDG uptake, indicating successful chemotherapy, although MRI findings were little changed. Four patients who had newly developed lesion on PET during the follow-up period showing CR turned out to have recurred, with rapid increase of FDG uptake. Those cases who were detected to have recurred resumed salvage high-dose chemotherapy with autologous hematopoietic stem-cell transplantation.
|
Our results suggested that PET scanning is a useful method in treatment evaluation of PBL. FDG-PET will provide major contribution in the decision-making of further management in PBL.
Department of Internal Medicine, Division of Haematology and Oncology, Korea Institute of Radiological and Medical Sciences, 2154, Gongneung-Dong, Nowon-Ku, Seoul 139-706, Korea
(* Email: yhpark{at}kcch.re.kr)
Acknowledgements
This abstract was presented at the 29th ESMO Congress and published in Abstract Book of the 29th ESMO Congress, Vienna, Austria, October 29 to November 2, 2004. A travel grant (ESMO Congress Committee) was awarded to enable attendance of the Meeting.
Notes
Y.H. Park and S. Kim contributed equally to this work
References
1. Hicks DG, Gokan T, O'Keefe RJ et al. Primary lymphoma of bone. Cancer 1995; 75: 973980.[ISI][Medline]
2. Heyning FH, Hogendoorn PCW, Kramer MHH et al. Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia 1999; 13: 20942098.[CrossRef][ISI][Medline]
3. Barr J, Burkes RL, Bell R et al. Primary non-Hodgkin's lymphoma of bone. Cancer 1994; 73: 11941199.[ISI][Medline]
4. Mulligan ME, McRae GA, Murphey MD. Imaging features of primary lymphoma of bone. AJR Am J Roentgenol 1999; 173: 16911697.[Abstract]
|